Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
← catalyst calendarSponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Phase 1/2
Status
Unknown status
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
150estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-08 | actual | When the study began enrolling |
| Primary completion | Aug 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Progressive Keratoconus
Interventions
- Combination product: NXL Energy 1
- Combination product: NXL Energy 2
- Combination product: NXL Energy 3
- Combination product: Sham Treatment
Primary outcome
what the primary-completion date above is the date OFTopography
measured 12 Months
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed